I hope you enjoy reading this blog post.

If you want to get access to our carefully selected top 3 researches click here.

  • Home
  • /
  • Blog
  • /
  • Understanding the Signatera Test: A New Frontier in Cancer Recurrence Detection

Imagine feeling the looming cloud of doubt and anxiety that follows a successful course of cancer treatment. The fear of cancer returning is a constant companion, and the suspense-filled wait between regular check-ups can seem unbearable. Enter the Signatera Test – a breakthrough in the field of oncology that aims to detect the possibility of cancer recurrence at the earliest possible stage, offering peace of mind and a beacon of hope to many.

Key Takeaways

  • The Signatera Test is a bespoke blood test that tracks molecular residual disease (MRD) by detecting circulating tumor DNA (ctDNA), aiding in the identification and monitoring of cancer recurrence.

  • By analyzing ctDNA to track MRD, the Signatera Test allows for earlier detection of cancer recurrence and more informed treatment decisions, potentially improving patient outcomes and survival rates.

  • The Signatera Test offers a non-invasive alternative to traditional imaging, providing personalized, sensitive monitoring of cancer, and may be particularly effective in solid tumors, including colorectal, lung, breast, and bladder cancers.

The Signatera Test Explained

Illustration of cancer cells in a patient's blood

The Signatera Test, a personalized blood test, marks a new stage in cancer monitoring by specifically detecting the presence of molecular residual disease (MRD) in cancer patients. This revolutionary test analyzes circulating tumor DNA (ctDNA), identifying specific DNA mutations present in the tumor to create a unique tumor signature. The test monitors MRD progression over time by comparing ctDNA in subsequent blood samples to this baseline signature, providing a non-invasive method to detect and monitor cancer.

A positive Signatera Test result, which detects ctDNA, might indicate a higher risk of cancer recurrence. Conversely, a negative result, signifying the absence of ctDNA, could imply that the treatment has successfully reduced cancer cells to undetectable levels, providing hope for individuals battling the disease.

What is Molecular Residual Disease?

Molecular Residual Disease (MRD) is defined as the residual presence of cancer cells, as indicated by ctDNA, that persist in the body following treatment and have the potential to cause cancer recurrence. The detection of MRD is achieved through the measurement of ctDNA in circulation, or by analyzing plasma circulating cell-free DNA (cfDNA), offering a non-invasive approach to identify molecular residual disease. This method, known as a residual disease test, is particularly useful for solid tumors.

Negative MRD results signify the absence of detectable residual disease, indicating a reduced risk of cancer recurrence. In contrast, positive MRD results indicate the existence of residual disease, potentially requiring supplementary or more intensive treatments. This holds particular relevance for patients with stage III colorectal cancer, as survival rates can be significantly impacted by early detection and treatment adjustments.

Personalization through Tumor DNA

The creation of a personalized assay in the Signatera Test involves collecting the patient’s own tumor tissue, and it is this tissue determines the development of a personalized blood test to detect cancer recurrence earlier. This personalized assay is particularly useful for patients with muscle invasive bladder cancer, where early detection of recurrence can significantly impact treatment outcomes.

Tumor DNA, particularly ctDNA, plays a significant role in the detection of cancer recurrence. It has demonstrated potential in detecting minimal residual disease (MRD) and monitoring response to treatment. The Signatera Test provides highly accurate identification of minimal residual disease by detecting minute quantities of tumor DNA in the blood before conventional imaging techniques can visibly detect cancer recurrence. This approach, informed by tumor data, helps in excluding CHIP mutations and minimizing false positives, thereby increasing the specificity and sensitivity of the test.

Benefits of Early Detection

The early detection of cancer recurrence permits swift intervention, which could potentially lead to improved patient outcomes. Research has indicated that early detection, particularly for breast cancer recurrences, can result in a notable reduction in mortality, with reported reductions of 17-28%. Improved survival rates have been linked to earlier detection through different methods, and current guidelines advise regular surveillance for early identification of locoregional recurrences.

Some key points to consider about the early detection of cancer recurrence are:

  • Swift intervention can lead to improved patient outcomes

  • Early detection of breast cancer recurrences can reduce mortality by 17-28%

  • Different methods can be used for early detection

  • Regular surveillance is advised for early identification of locoregional recurrences

Early cancer detection offers several benefits, including:

  • Enlarging the pool of treatment options

  • Increasing the chances of successful interventions

  • Slowing or preventing cancer progression and fatality

  • Potentially improving the patient’s quality of life.

The Role of ctDNA in Cancer Monitoring

Photo of a blood sample collection

Circulating tumor DNA, or ctDNA, denotes small fragments of DNA originating from cancer cells that have been discharged into the bloodstream. The levels of ctDNA serve as an indicator for the presence or progression of cancer. Elevated ctDNA levels frequently signify active cancer, while a reduction in these levels may suggest a favorable response to treatment.

Within the multifaceted field of cancer monitoring, ctDNA has surfaced as a key component. Its transition from the primary tumor to the bloodstream and its function in monitoring treatment response have established its place as a useful instrument in combating cancer.

From Primary Tumor to Bloodstream

CTDNA enters the bloodstream through various mechanisms, such as direct tumor invasion into the vasculature, shedding of cells from the primary tumor, and the release of nucleic acids into body fluids. These mechanisms facilitate the presence of ctDNA, fragmented DNA molecules, in the blood, and their use as indicators of primary or metastatic cancer sites.

The detection of ctDNA in the bloodstream is variable, with possible identification as early as 48 to 72 hours after specific treatments such as plaque brachytherapy. Moreover, within 4 months post-treatment completion, ctDNA may be detectable in individuals with localized lung cancer. Identifying ctDNA in the bloodstream is crucial, as it enables the analysis of genetic mutations from tumor tissue, offering a non-invasive means of dynamically observing cancer progression.

Tracking Treatment Response with ctDNA

The role of ctDNA in predicting the effectiveness of cancer treatments is significant. It provides early and reliable indicators of treatment response and survival in patients undergoing therapy. Some key points about ctDNA include:

  • A reduction in ctDNA levels within the initial few days of treatment implies a beneficial response to the therapy.

  • ctDNA can guide decisions such as whether to administer adjuvant chemotherapy.

  • ctDNA is detectable in various cancer types, including those treated with immunotherapy.

Alterations in ctDNA levels during cancer treatment signal the treatment’s efficacy. A reduction in ctDNA levels at the start of treatment is linked to a beneficial treatment response. This informed approach, guided by ctDNA tracking, aims to enhance treatment strategies and ultimately improve patient outcomes by enabling adjustments to current therapies, consideration of new treatments, or the pursuit of additional interventions like surgery or radiation.

The Signatera Test Process

Illustration of data analysis for the Signatera Test

The Signatera Test process, from drawing a blood sample to interpreting the results, is a precise and careful journey. This process is not solely about identifying molecular residual disease; it’s about providing insights that direct patient care, empowering more knowledgeable decisions about treatment strategies.

Collecting the Sample

The standard procedure for collecting a patient’s blood sample for the Signatera Test involves drawing blood from a patient’s vein, usually located in the arm. Prior to taking the Signatera test, it is recommended to ensure that blood samples are collected 2 weeks post any surgical procedure.

During the Signatera sample collection process, patient identification is ensured by meticulously de-identifying blood samples to protect patient privacy. An important part of this process is the meticulous handling and transportation of the samples, undertaken in accordance with the vendor’s guidelines.

Analyzing the Data

Upon arrival at the lab, the blood sample is subjected to a comprehensive analysis process. The Signatera Test employs whole-exome sequencing of the individual’s primary tumor to identify specific mutations and compares this data to a blood sample using highly sensitive bioinformatics software to detect circulating tumor DNA (ctDNA).

The level of reliability associated with ctDNA detection using the Signatera Test was 53% in a recent study. It is contingent upon the following factors:

  • The test being performed in a timely manner

  • Sample collection taking place at an optimal time

  • Levels of ctDNA in the plasma

  • Sequencing depth

  • Tumor burden

  • The cancer stage and whether it has metastasized

  • Various technical and preanalytical factors

These factors can impact the precision of ctDNA analysis.

Understanding Your Test Results

Upon completion of data analysis, the Signatera Test results are presented. A positive test result, indicating the detection of tumor DNA in the blood, could suggest a higher risk for cancer recurrence. Conversely, a negative result, indicating the absence of tumor DNA, offers reassurance of no microscopic disease and influences treatment decisions to potentially avoid unnecessary interventions.

The amount of ctDNA is significant as it mirrors the level of residual disease. Higher quantities imply an increased risk of cancer recurrence, while lower quantities suggest a reduced risk. The Signatera Test is highly reliable for predicting cancer recurrence, especially in colorectal cancer, where a positive result indicates a 97% risk of recurrence. It has demonstrated the ability to detect relapse earlier than conventional diagnostic methods in a range of cancer types.

Real-Life Impact of the Signatera Test

Illustration of positive impact on patients' lives

Beyond the scientific and statistical aspects, the real success of the Signatera Test is measured by its impact on the lives of the individuals it serves. Patients who have taken the test reported reduced anxiety and increased confidence in their treatment plans, finding that the test offers peace of mind and useful insights into disease recurrence.

The Signatera Test has had a positive effect on patients’ mental health by offering comfort and reassurance, alleviating stress and anxiety associated with cancer monitoring, and allowing patients to feel more in control of their health status. It has also improved the quality of life for patients by enabling early detection of cancer recurrence, which allows for prompt and tailored intervention, helping ensure better overall survival rates and offering a more personalized approach to treatment management.

Patients’ Experiences

Most patient experiences with the Signatera Test have been positive. While some have felt increased peace of mind, others have reported anxiety. Negative results have brought relief and reduced anxiety, while positive results have led to high levels of anxiety. However, overall, patients have expressed appreciation for the early detection of recurrence and the ability to monitor their cancer status.

Signatera Test results have been instrumental in guiding patients’ treatment decisions, allowing them to evaluate treatment response, identify recurrence at a sooner stage, and modify treatment strategies as needed. This has facilitated a more personalized and potentially effective approach to their cancer care. Patients have also acquired meaningful insights into the potential of circulating tumor DNA (ctDNA) to predict cancer recurrence.

The Signatera Test has proven useful for various types of cancers, including colorectal and anal squamous cell carcinoma. Its ability to track minimal residual disease (MRD) provides patients with reassurance by supplying timely information about their disease status.

Empirical Evidence

Empirical evidence supports the effectiveness of the Signatera Test in detecting cancer recurrence earlier than traditional methods. Numerous studies have supported the effectiveness of the Signatera Test over imaging for early cancer detection. These studies have revealed that Signatera can identify molecular residual disease (MRD) up to 2 years earlier than standard imaging methods.

The Signatera Test, which utilizes plasma cell free dna, has shown remarkable specificity, with a reported rate of zero false positives across tested plasma samples, resulting in an overall specificity of 100%. It also demonstrates superior performance compared to traditional cancer monitoring methods, with a specificity of over 90% that enables accurate identification of true negatives and true positives.

Comparing Signatera to Traditional Methods

Illustration comparing Signatera to traditional methods

While traditional methods of cancer monitoring, such as periodic health exams, screening tests, imaging tests, and lab tests, have their place in cancer care, they have certain limitations. The Signatera Test, on the other hand, offers a significant advantage over these methods.

As a circulating tumor DNA (ctDNA) assay, it has the ability to identify residual disease and signal cancer recurrence at an earlier stage than traditional imaging scans such as CT and PET scans.

Advantages Over Imaging

The Signatera Test:

  • Identifies cancer recurrence earlier than imaging

  • Detects circulating tumor DNA (ctDNA) in the blood

  • Can detect molecular recurrence up to 16.5 months earlier than standard-of-care radiologic imaging.

Numerous studies have supported the effectiveness of the Signatera Residual Disease Test over imaging for early cancer detection. These studies have revealed that Signatera can:

  • Identify molecular residual disease (MRD) up to 2 years earlier than standard imaging methods

  • Utilize personalized and tumor-informed ctDNA testing

  • Demonstrate promising potential as a minimally invasive method for real-time disease monitoring and early detection.

The implications of this early detection for timely intervention in cancer treatment are significant.

Complementing Other Tests

The Signatera Test augments traditional cancer diagnostic methods by providing a personalized blood test that investigates circulating tumor DNA (ctDNA) to recognize residual disease or recurrence, supplementing commonly used diagnostic tools such as imaging tests and flow cytometry.

The Signatera Test contributes specific details regarding minimal residual disease (MRD) and circulating tumor DNA (ctDNA) tailored to the individual patient’s tumor mutations. These details can aid in:

  • Earlier detection of relapses compared to standard diagnostic tools

  • Offering clinical benefits by detecting and evaluating the extent of cancer in the body

  • Detecting recurrence at an earlier stage

  • Aiding in the customization and optimization of treatment approaches.

When to Consider the Signatera Test

The Signatera Test is particularly suitable for individuals who have been diagnosed with cancer, specifically those with solid tumor cancers such as colorectal, non-small cell lung, breast, among others, and who aim to manage cancer recurrence or evaluate treatment effectiveness. It demonstrates its highest effectiveness in identifying cancer recurrence and minimal residual disease in patients with colorectal cancer at stages II and III.

The Signatera Test is appropriate for all types of solid tumor cancers. This personalized blood test is capable of detecting tumor-specific mutations, enabling the identification of molecular residual disease or cancer recurrence.

Who Can Benefit?

The Signatera test has the capacity to forecast the recurrence of solid tumor cancers, encompassing lung, colon, bladder, and breast cancer. It is capable of detecting colorectal cancer and has demonstrated potential in monitoring neoadjuvant treatment response in breast cancer patients and identifying residual disease.

Timing and Frequency of Testing

Typically, the Signatera test is conducted every 3 months for regular monitoring, but the frequency can be adjusted by the doctor depending on the treatment response. Patients undergoing chemotherapy or radiation treatment are typically tested every 3 months as well.

Optimal timing can enhance the effectiveness of detecting minimal residual disease.


In the challenging journey of cancer treatment and monitoring, the Signatera Test stands out as a beacon of hope. It provides a personalized, non-invasive method for early detection of cancer recurrence, granting patients peace of mind and an empowering sense of control over their health. With its ability to detect molecular residual disease, monitor treatment response, and guide clinical decisions, the Signatera Test is revolutionizing the field of oncology.

This breakthrough technology not only enhances the possibilities of early intervention and tailored treatment strategies but also addresses the psychological well-being of patients, reducing anxiety and providing reassurance. As we continue to innovate and refine these diagnostic tools, the future of cancer care holds the promise of improved patient outcomes and a higher quality of life.

Frequently Asked Questions

What is a Signatera test for?

The Signatera test is used to identify molecular residual disease (MRD) or recurrent cancer by detecting circulating tumor DNA (ctDNA) based on each patient’s unique set of tumor mutations. It can detect cancer recurrence sooner than existing methods.

How accurate is the Signatera blood test?

The Signatera blood test is highly sensitive and specific, but it is not 100% accurate in predicting cancer progression status, so a negative result does not guarantee that the cancer is cured or that it won’t recur in the future.

Is Signatera test covered by insurance?

Yes, Signatera test is covered by Medicare for certain cancer patients for monitoring disease progression, recurrence, or response to treatment.

How much does a ctDNA test cost?

A ctDNA test typically costs around $500 per test, similar to other tests like the Epstein-Barr virus DNA test.

Can the Signatera Test detect all types of solid tumor cancers?

Yes, the Signatera Test can detect all types of solid tumor cancers by identifying tumor-specific mutations in the blood.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}